OPKO Health (NASDAQ:OPK) Rating Lowered to Sell at StockNews.com

StockNews.com lowered shares of OPKO Health (NASDAQ:OPK) from a hold rating to a sell rating in a report issued on Wednesday.

OPK has been the subject of several other research reports. Piper Sandler reissued an “overweight” rating and set a $3.00 price target on shares of OPKO Health in a research report on Tuesday, September 17th. HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a report on Wednesday, January 8th. Finally, Barrington Research reaffirmed an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a report on Friday, November 8th.

OPKO Health Stock Performance

Shares of OPK stock opened at $1.47 on Wednesday. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The company’s fifty day moving average price is $1.54 and its 200-day moving average price is $1.50. The stock has a market cap of $1.00 billion, a PE ratio of -7.74 and a beta of 1.63. OPKO Health has a 12 month low of $0.86 and a 12 month high of $1.76.

Insider Activity

In related news, CEO Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock in a transaction dated Thursday, November 14th. The stock was purchased at an average cost of $1.62 per share, for a total transaction of $162,000.00. Following the purchase, the chief executive officer now directly owns 211,612,405 shares of the company’s stock, valued at approximately $342,812,096.10. This trade represents a 0.05 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders acquired 1,804,255 shares of company stock valued at $2,764,605 in the last quarter. 47.26% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Hollencrest Capital Management grew its stake in shares of OPKO Health by 14.0% during the 2nd quarter. Hollencrest Capital Management now owns 90,000 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 11,020 shares during the period. FMR LLC boosted its position in shares of OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares during the period. Private Advisor Group LLC boosted its position in shares of OPKO Health by 242.7% in the third quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 25,000 shares during the period. Orion Portfolio Solutions LLC bought a new stake in shares of OPKO Health during the 3rd quarter valued at $45,000. Finally, Algert Global LLC bought a new position in OPKO Health in the 2nd quarter worth $44,000. Institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.